🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Relapsed/Refractory Immune Thrombocytopenia

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: UCAR T-cell CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: QT-019C An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site📍 Shanghai Shanghai Cell Therapy Group Co.,Ltd · Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia NCT05599880Phase 24 sites📍 Guri-si📍 Seoul📍 Seoul Seoul National University Hospital · Tests: Bortezomib A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia NCT07175493Phase 1, Phase 23 sites📍 Zhengzhou📍 Changzhi📍 Tianjin Keymed Biosciences Co.Ltd · Tests: CM336 Injection RN1201 Injection in the Treatment of Antibody-Mediated Diseases NCT07072247Phase 11 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: CD19 and BCMA-targeted allogeneic CAR-T cells Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease NCT07549698Phase 1, Phase 212 sites📍 Boston📍 Rochester📍 Omaha CRISPR Therapeutics AG · Tests: CTX112 Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia NCT06973356NA1 site📍 Changsha Anhui Provincial Hospital · Tests: Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy